Infection with any 1 of 4 dengue viruses produces a spectrum of clinical illness ranging from a mild undifferentiated febrile illness to dengue fever (DF) to dengue hemorrhagic fever (DHF), a potentially life-threatening disease. The morbidity and mortality of DHF can be reduced by early hospitalization and careful supportive care. To determine its usefulness as a predictor of DHF, plasma levels of the secreted dengue virus nonstructural protein NS1 (sNS1) were measured daily in 32 children with dengue-2 virus infections participating in a prospective, hospital-based study. Free sNS1 levels in plasma correlated with viremia levels and were higher in patients with DHF than in those with DF. An elevated free sNS1 level (у600 ng/mL) within 72 h of illness onset identified patients at risk for developing DHF.
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Dengue, an emerging arboviral and arthropodborne disease, is a major cause of morbidity throughout the tropical and subtropical regions of the world [1] . Dengue virus (DV) infection with any 1 of 4 serotypes produces a spectrum of clinical illness, ranging from an asymptomatic or mild febrile illness to classic dengue fever (DF) to the most severe form of illness, dengue hemorrhagic fever (DHF). DHF is characterized by plasma leakage and a hemorrhagic diathesis near the time of defervescence, typically after 5 days of fever [2] . In severe DHF, morbidity and mortality are the results of hypotension and shock, at times accompanied by severe coagulation abnormali- The investigational protocol was approved by the institutional review boards of the Thai Ministry of Public Health, the Office of the US Army Surgeon General, and the University of Massachusetts Medical School. Parents or guardians of all study subjects gave written informed consent.
The contents of this publication are solely the responsibility of the authors and do not necessarily represent the official views of the National Institutes of Health (NIH) or the US Department of Defense. ties and bleeding. Since early hospitalization and careful supportive care can reduce the case-fatality rate of DHF, the rapid identification of patients at risk for developing DHF is desirable in regions where DV is endemic.
Most DHF cases occur after sequential heterotypic DV infections (secondary infection) [3] , and circulating DV levels early in illness correlate with increasing dengue disease severity [4, 5] . The DV nonstructural protein NS1 is a 46-50-kDa glycoprotein expressed in infected mammalian cells in both membrane-associated (mNS1) and secreted (sNS1) forms and is not a component of the dengue virion [6] . Circulating sNS1 has been detected in acute-phase serum samples of patients with DV infections [7, 8] .
In DV-infected cell cultures, supernatant levels of sNS1 correlate with infectious virus titers [8] . The goals of this study were to determine whether plasma levels of sNS1 correlate with viremia levels, whether they are higher in DHF than in DF, and whether sNS1 levels early in illness could identify patients at risk of developing DHF.
Patients and Methods
Subject enrollment and study design. Subjects with dengue-2 virus (D2V) infection were selected for this study from children participating in a prospective, hospital-based, study of dengue in Thailand during 1995-2000 [9] . Enrollment criteria were ages 6 months to 14 years, a febrile illness with !72 h of symptoms, no hypotension or shock, and no other obvious source of infection. Children were observed in the hospital until у1 day after defervescence. Venous blood samples were drawn daily, up to the day after defervescence or for a maximum of 5 consecutive days and 8-13 days after enrollment. Plasma aliquots were stored at Ϫ70ЊC. Illness day 1 was defined as the calendar day when fever began, as determined by history. Primary or secondary DV infections were identified by use of previously established serologic criteria for IgM/ IgG ELISAs and hemagglutination inhibition assays to DV serotypes 1-4 (D1V-D4V) and Japanese encephalitis virus in paired plasma specimens [10, 11] . D2V infection was identified by virus isolation in Toxorhynchites splendens mosquitoes or by serotypespecific reverse transcriptase-polymerase chain reaction (RT-PCR) assay [4] . A clinical diagnosis of DF or DHF and severity grading (grades I-IV) were assigned according to World Health Organization criteria [11] . Quantification of viremia and sNS1 levels. The circulating level of viral RNA (viremia) was quantified in consecutive daily plasma samples by using a serotype-specific fluorogenic RT-PCR assay [12] . A 143-nt amplicon of the D2V 3 -noncoding region (the RT-PCR product) [12] was cloned into a pNOT vector, and serial dilutions were used as quantification standards. Viremia levels were expressed as D2V genome equivalent cDNA copies per milliliter. The assay limit of detection was 4.80 log D2V genome equivalent cDNA copies/mL. The maximum viremia level was defined as the highest plasma viremia level measured during illness. Free (antibody unbound) D2V sNS1 levels were determined in consecutive daily plasma samples by capture ELISA [8] . Samples were screened initially at a 1:10 dilution, and positive samples then were serially diluted. Serial dilutions of immunoaffinity purified D2V NS1 were used as quantification standards; the assay's limit of detection was 4 ng/mL. All samples were assayed in duplicate (sNS1) or triplicate (viral RNA copy number) in a blinded fashion and were quantified on the linear portion of standard curves. The maximum sNS1 level also was defined as the highest plasma sNS1 level measured during illness. The maximum sNS1 level was considered to be a peak sNS1 level only in cases where the plasma sNS1 level increased after study day 1.
Statistical analysis. We used the Student's t test for comparisons between normally distributed continuous variables and the Mann-Whitney U test for comparisons between continuous variables not normally distributed. x 2 analysis was used for comparisons among proportional data. We used the Pearson's correlation test to examine associations among continuous variables. P ! .05 was considered to be significant; was considered to .05 у P р .10 be a nonsignificant trend. For all statistical analyses, we used the SPSS version 10.0 software package.
Results
During 1995-2000, 726 children were enrolled in our prospective study, and 77 were identified with an acute D2V infection. We selected a subset of 32 children with D2V infection (DF, ; DHF grades I/II, ; and DHF grade III, n p 14 n p 16 ) for this analysis, without previous knowledge of viremia n p 2 or sNS1 levels. The median age of these children was 9.5 years (range, 2.9-13.5 years); the male:female ratio was 2.2:1. There were no differences in age, sex, or day of illness on study entry between the DHF and DF groups (data not shown). In keeping with the pattern in the overall study [4] , all 32 subjects were experiencing a secondary D2V infection.
Mean plasma levels of free sNS1 were highest early in clinical illness and were higher in DHF than in DF on illness days 3 ( ) or 4 ( ) and trended higher on illness day 5 P p .003 P p .02 ( ; figure 1A) . Mean dengue-2 viremia levels also were P p .10 greatest early in clinical illness and were higher in DHF than in DF on illness days 3-6 ( , [nonsignificant P p .04 P p .06 , ⅷ) and dengue hemorrhagic fever (DHF, ; ࡗ). Open symbols represent cases at n p 14 n p 18 or below limit of detection (40 ng/mL). Cutoff value shown for prediction of DHF, 600 ng/mL. trend],
, and for illness days 3-6, respectively; P p .03 P p .01 figure 1B ). In D2V infections (DF and DHF), increased circulating levels of free sNS1 correlated with higher viremia levels on a daily basis (log sNS1 vs. log viral RNA levels on each illness day 3, 4, and 5, Pearson , ; illness day 6, r p 0.7 P ! .001 Pearson , ), and at maximum values (log maxr p 0.5 P p .01 imum sNS1 vs. log maximum viral RNA levels, Pearson r p ; ). The increase and decrease of free sNS1 in plasma 0.6 P ! .001 tended to lag plasma levels of viral RNA. In cases where a peak sNS1 level was identified (DHF, ; DF, ), free n p 13 n p 7 sNS1 levels peaked on illness day 4 (mean/median, day 4; range, day 3-6) and followed maximum viremia levels by 1.0 ‫ע‬ 0.7 days ( ; no significant difference between DHF and mean ‫ע‬ SD DF, data not shown).
Of the 32 children, 28 (88%) had detectable free sNS1 during the febrile phase of illness. At study entry (within 72 h of illness onset), 10 (71%) of the 14 patients with DF and 16 (89%) of the 18 patients with DHF had detectable free sNS1 levels. No patient had a diagnostic anti-DV IgM level on study entry. A free sNS1 level у600 ng/mL on presentation predicted the subsequent development of DHF with a sensitivity of 72% and a specificity of 79% (figure 2). The positive predictive value of an initial free sNS1 level у600 ng/mL for the development of DHF was 81%; the negative predictive value was 69%.
Discussion
We used a quantitative antigen-capture ELISA for D2V sNS1 to demonstrate that free circulating levels of D2V sNS1 correlate with viremia levels and are higher in DHF than in DF early in illness. The ability to identify, at initial presentation, patients with DV infection who are at risk for developing DHF would be an important step in improving the clinical management of dengue. This could reduce unnecessary hospitalization of patients with milder disease and allow for early hospitalization and supportive care of those developing potentially lifethreatening DHF.
Quantification of viremia by RT-PCR methods might be useful in this regard but is expensive and not readily available in endemic regions. Anti-DV IgM serologic testing may not become diagnostic until after defervescence [2, 10] and is unlikely to be useful in disease severity stratification. The early clinical syndrome of dengue is generally indistinguishable in persons developing DF or DHF and is similar to several common tropical illnesses, such as leptospirosis, typhoid, rickettsioses, or other childhood viral illnesses. Quantitative determinations of plasma aminoaspartate (AST) levels and circulating soluble tumor necrosis factor receptor (sTNFR80 or sTNFR75) levels have been proposed previously as predictors of DHF [9, 13] or DHF with shock [14] . In usual clinical practice where early dengue diagnosis is not feasible, the rapid detection of hepatic transaminase or soluble cytokine receptor levels would be inherently nonspecific. The detection and quantification of circulating free sNS1, a virally encoded protein, can provide a specific diagnosis of DV infection and potentially predict the development of DHF before the anti-DV IgM serologic testing becomes diagnostic.
Further evaluation of this sNS1 assay is needed in a larger cohort that includes bacterial, rickettsial, and other viral, nondengue, acute febrile illnesses. The sensitivity, specificity, and predictive values of D2V sNS1 for DHF in this study, which included only subjects with secondary D2V infections, were better than the values reported for AST and sTNFR80 in previous studies from our group that examined predominantly D1V and D2V infections [9, 13] . A semiquantitative, rapid, ELISA-based assay for detection of sNS1 levels is feasible for endemic regions and could provide both early diagnosis of DV infections and dengue disease severity stratification.
A recent report described an antigen-capture ELISA for D1V sNS1 and reported serum sNS1 levels early in primary and secondary D1V infections of 10 ng/mL-2 mg/mL [7] . Consistent with our findings, the authors reported peak levels of circulating sNS1 between illness days 3-5 in 4 patients who had consecutive daily determinations of serum sNS1 levels. However, viremia levels were not assessed by quantitative RT-PCR, and no associations between circulating sNS1 levels and disease severity were made, since all cases were classified as DF.
We probably underestimated the lag between the time to peak circulating levels of free sNS1 protein, compared with that of viral RNA, since viremia levels already were decreasing at study entry in most cases. The later appearance of peak free sNS1 levels may be due to a slower rate of sNS1 protein production, compared with that of viral RNA in infected cells, a slower rate of sNS1 protein clearance from plasma, compared with clearance of viral RNA, or both. In secondary infections, a significant amount of sNS1 may be antibody bound during acute illness. In our patient cohort, the clearance of circulating free sNS1 protein also may have been a consequence of sNS1 being trapped within immune complexes, which impedes detection in our assay [8] . Preliminary attempts to dissociate antibody-bound sNS1 for further analysis proved to be difficult [8] ; alternative procedures are currently under investigation.
Immune complex formation with sNS1 [8] and sNS1 binding to endothelial cells [15] have been proposed as potential factors in DHF pathogenesis. Whether high circulating levels of antibody-bound or free sNS1 protein following peak viremia play a direct role in the pathogenesis of DHF is unknown and will require further investigation.
Additional studies also are needed to evaluate quantitative sNS1 assays in DF and DHF caused by serotypes other than D2V, as well as in primary infections with D2V. An earlier study by one of us (P.R.Y.) did not detect serum sNS1 levels in single acute illness specimens from 6 patients with primary D2V infection [8] . However, these specimens probably were collected late in illness and all were from patients with DF, since DHF is rarely seen with primary D2V infection. With the development of either serotype-specific or serotype cross-reactive sNS1 assays, cutoff values for differentiating DHF from DF early in illness could be determined in patient cohorts with D1V-D4V infections and then be validated in prospective studies.
